Analysts Offer Insights on Financial Companies: Baldwin Insurance Group (BWIN) and Trupanion (TRUP)
There's a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Baldwin Insurance Group (BWIN – Research Report) and Trupanion (TRUP – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Baldwin Insurance Group (BWIN)
William Blair analyst Adam Klauber maintained a Buy rating on Baldwin Insurance Group yesterday. The company's shares closed last Tuesday at $40.40.
According to TipRanks.com, Klauber is a 4-star analyst with an average return of 10.4% and a 60.0% success rate. Klauber covers the Financial sector, focusing on stocks such as Skyward Specialty Insurance Group, Inc., Marsh & Mclennan Companies, and Arthur J Gallagher & Co.
Baldwin Insurance Group has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.
Trupanion (TRUP)
William Blair analyst Brandon Vazquez maintained a Buy rating on Trupanion today. The company's shares closed last Tuesday at $49.38.
Trupanion has an analyst consensus of Moderate Buy, with a price target consensus of $51.00.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
19 hours ago
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: Quince Therapeutics (QNCX) In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17. According to McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target. Moderna (MRNA) In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46. According to Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc. Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Consumer Cyclical Companies: Five Below (FIVE) and Autoliv (ALV)
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Five Below (FIVE – Research Report) and Autoliv (ALV – Research Report). Confident Investing Starts Here: Five Below (FIVE) Barclays analyst Seth Sigman maintained a Hold rating on Five Below on June 5 and set a price target of $120.00. The company's shares closed last Friday at $127.35. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.0% and a 53.9% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. Five Below has an analyst consensus of Moderate Buy, with a price target consensus of $118.63, which is a -7.0% downside from current levels. In a report issued on May 28, Citi also maintained a Hold rating on the stock with a $121.00 price target. Autoliv (ALV) Kepler Capital analyst Alexandre Raverdy maintained a Buy rating on Autoliv on June 5 and set a price target of $100.00. The company's shares closed last Friday at $105.62. According to Raverdy is ranked #5408 out of 9607 analysts. Autoliv has an analyst consensus of Strong Buy, with a price target consensus of $111.31, a 4.8% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $123.00 price target.
Business Insider
3 days ago
- Business Insider
William Blair Sticks to Their Buy Rating for Yeti Holdings (YETI)
William Blair analyst Phillip Blee maintained a Buy rating on Yeti Holdings (YETI – Research Report) today. The company's shares closed today at $31.39. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Blee is a 3-star analyst with an average return of 7.2% and a 57.89% success rate. Blee covers the Consumer Cyclical sector, focusing on stocks such as Costco, Traeger, and RH. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Yeti Holdings with a $35.43 average price target.
